Skip navigation
>»
RSS feed for this page
Know something we don't? Submit a conference announcement
Choose Category:

HIV/AIDS meetings & conferences

7 meetings & conferences listed in HIV/AIDS 

8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015)
Canada
07/19/2015

8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015)

19-22 July 2015 Vancouver, British Columbia, Canada

The 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) will be held at the Vancouver Convention Centre on 19-22 July 2015 in Vancouver, British Columbia, Canada. This biennial forum is the largest open scientific conference on HIV/AIDS related issues and is expected to gather some 6,000 delegates from across the globe.

IAS 2015 will be a unique opportunity for all those involved in the global response to HIV, including scientists, clinicians, public health experts, community leaders, and media professionals, to meet and examine the latest scientific developments in HIV-related research, and explore how such developments can be realistically applied in implementation programmes.

IAS 2015 is organized by the International AIDS Society (IAS), in partnership with the University of British Columbia (UBC) Division of AIDS, based at St. Paul’s Hospital, Providence Health Care. The Division was created in 2007 to bring together, enhance and expand the research, training, service delivery and administration that have evolved over the last two decades within the UBC Department of Medicine and Providence Health Care.

Community Activist, Nurse, Nurse Researcher, Physician, Physician Researcher, Public Health Expert, Public Health Worker, Public Servant
2015 National HIV Prevention Conference
United States
Washington, DC
12/06/2015

2015 National HIV Prevention Conference

December 6-9, 2015 Atlanta, Georgia

The 2015 National HIV Prevention Conference is a collaboration between several federal agencies, local governments and other organizations. It is the preeminent conference for state and local health departments, community based organizations, federal agencies, researchers, clinicians, people living with HIV and others to share the latest advancements, strategies and accomplishments in HIV prevention and care.

The National HIV Prevention Conference allows for in-person collaboration between researchers and program personnel planning and implementing HIV prevention and care programs.  The conference will bring together more than 3,000 individuals who are working to stop the domestic spread of HIV. It will provide an opportunity to continue refining, improving, and strengthening our nation’s response to HIV.

This four-day conference will include plenary sessions, workshops, roundtables and poster presentations and is a platform for conference participants to engage in rigorous scientific, programmatic, and technology information exchange.

For questions, contact us at questions@NHPC2015.com

Community Activist, Health Educator, Health Services Researcher, Nurse, Patient, Physician, Physician Researcher, Public Health Expert, Public Health Worker, Public Servant
Mechanisms of HIV Persistence: Implications for a Cure
United States
Massachusetts
04/26/2015

Mechanisms of HIV Persistence: Implications for a Cure

April 26—May 1, 2015 Boston, Massachusetts

Despite long-term control of HIV replication with cART, HIV persists as silenced integrated DNA in memory CD4 T cells, and possibly in other cellular reservoirs, including naïve cells and macrophages. Low level replenishment of the reservoir via limited cycles of replication, may also contribute to persistence, at least in some patients. Curing HIV infection will only occur if these barriers are reversed, or if host capacity to control HIV indefinitely is improved. A number of promising interventions which might reverse latent infection have been identified, and proof that such drugs affect HIV transcription in vivo provided in pilot clinical trials. The observation that few patients treated during primary infection control durably replication-competent HIV after interrupting therapy suggests host responses might be manipulated, leading to a functional cure. The path forward will require a detailed understanding of the mechanisms of viral latency which could lead to the identification of new drugs, and a better knowledge of the plasticity and dynamics of the main HIV cell reservoirs: CD4 T cells and macrophages. The role of the tissue microenvironment has to be underlined with the major help of non-human primate models. At the 2015 Keystone Symposia meeting on Mechanisms of HIV Persistence: Implications for a Cure, experts from both within and outside the HIV field will present findings from recent advances on immune mechanisms and therapeutic strategies which could lead to HIV cure.

Immunologist, Physician Researcher, Virologist
HIV Drug Therapy in the Americas 2015
Mexico
04/16/2015

HIV Drug Therapy in the Americas 2015

16-18 April 2015 Mexico City, Mexico

Pharmacologist, Physician Researcher, Public Health Expert
HIV Vaccines
Canada
03/22/2015

HIV Vaccines

Joint with the meeting on The Golden Anniversary of B Cell Discovery

March 22—27, 2015 Banff, Alberta, Canada

Registered attendees of one meeting in a joint pair may participate in sessions of the other, pending space availability.

As the 30th anniversary of the discovery of HIV has come and gone, HIV remains a catastrophic public health concern, with an estimated global prevalence of 34 million HIV-infected persons. Despite the remarkable advances in the development of several biomedical interventions for the prevention of HIV, the importance of developing an effective HIV vaccine has been recognized by a wide spectrum of the scientific community and civil society. Important milestones for the HIV vaccine field were the demonstration that a vaccine regimen could reduce HIV acquisition and the identification of binding IgG envelope (env) antibodies as potential correlates of protection from HIV acquisition. However, broad neutralizing antibodies (bNAbs) are thought to be the main mechanism of protection of the currently available effective vaccines. The present meeting will address the major scientific gaps in the the generation of env bNAbs. The major goals of the meeting include: 1) To understand the development of bNAbs in natural infections and following vaccination; 2) To determine predictors of response to vaccines; 3) To review the advances in envelope immunogen design; 4) The therapeutic use of bNAbs; 5) The application of novel technologies to monitor the immune response; and 6) The development of therapeutic strategies aimed to functional HIV cure. The meeting will bring together interdisciplinary groups with outstanding expertise in B- and T-cell biology, structural biology, vaccinology and clinical science. It will therefore provide to the attendees how innovative basic observations from the bench side may translate into the clinical development of vaccines and therapeutic interventions.

Physician Researcher, Virologist
Co-Infection: A Global Challenge for Disease Control
Brazil
03/15/2015

Co-Infection: A Global Challenge for Disease Control

March 15—20, 2015 Ouro Preto, MG, Brazil

Organized in collaboration with the Minas Gerais State Agency for Research Development (FAPEMIG) and the National Council for Scientific and Technological Development (CNPq) - Brazil. Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation

Multi-species co-infections impose one of the greatest challenges to global health and to our efforts to develop effective methods of infectious disease control. Populations living in rural areas of many low-income countries are exposed to both chronic and acute infection with multiple pathogens. In such conditions co-infection is common and the cause of additive or synergistic morbidities. Studying co-infections is difficult and complex as different pathogens may interact in many different ways, either directly or via the host immune response. Indeed, in some contexts, a community of organisms within a host may promote defense against other organisms. This Keystone Symposia meeting will focus on our current understanding of synergism/antagonism among pathogens causing common co-infections. In doing so it will bring together leading researchers and their knowledge of immune responses in co-infected individuals, co-infection immunoepidemiology, modeling of co-infections to predict disease and infection outcomes, and the specific challenges that co-infection presents to vaccine design strategies, and effective application of chemotherapy. This diversity of scientific disciplines will together address the impacts of co-infection, particularly in the context of the Neglected Tropical Diseases that are prevalent in many low- and middle-income countries. For example, in some of the poorest parts of the world, HIV, TB, leprosy, HTLV, malaria, dengue, and chronic helminth infections are co-endemic. To find the understanding and the means to effectively tackle the diverse clinical and public health problems of co-infection, we need to combine information derived from basic hypothesis-lead research, descriptive epidemiology and new computational modeling techniques. The goal of this symposium will be to broaden and deepen our understanding of within-host and population level interactions between different co-infecting pathogens and propose appropriate multidisciplinary strategies to move towards clinical and public health solutions, including the delivery of effective vaccination and chemotherapy.

Epidemiologist, Physician Researcher, Public Health Expert, Public Health Worker, Public Servant, Virologist
33rd Annual Meeting of the European Society for Paediatric Infectious Diseases
Germany
05/12/2015

33rd Annual Meeting of the European Society for Paediatric Infectious Diseases

May 12-16, 2015 Leipzig, Germany

Join 3,000 clinicians, researchers, residents, and students who come togethe​r each year for the Annual Meeting of the European Society for Paediatric Infectious Diseases. This year, our 33rd annual meeting (ESPID 2015) will be held on May 12-16 in dynamic Leipzig, Germany.

ESPID 2015’s scientific programme will consist of a range of sessions and learning opportunities, given by some of the top experts on Paediatric Infectious Diseases. Come discover the latest developments in our fast-changing world in Leipzig in 2015.​​​

Epidemiologist, Pediatrician, Pharmacologist, Physician, Physician Researcher, Virologist